Abstract:Background Data on the efficacy and safety of drug-eluting stent (DES) for treatment of multiple coronary chronic total occlusion (CTO) lesions are scanty. The aim of the present study was to compare the long-term outcomes of DES versus bare metal stent (BMS) implantation for multiple coronary CTO lesions.Methods We analyzed 188 patients who underwent coronary stenting for at least two de novo CTO lesions in our center from November 2000 to November 2006. Among them, 118 patients (62.8%) received DES and 70 patients (37.2%) received BMS implantation after the recanalization for CTO lesions. All patients were followed up for up to 5 years for the occurrence of major adverse cardiac events (MACE). Long-term survival rates were estimated with the Kaplan-Meier method.Results There were no significant differences in baseline clinical characteristics and procedural success rate between DES group and BMS group. Compared with the BMS group, the DES group showed a significantly higher rate of long CTO (>= 15 mm) (62.0% vs. 50.6%, P=0.023). The number of stents per lesion (1.39 +/- 0.71 vs. 1.17 +/- 0.66, P=0.007) and the mean length of stents in the DES group were also higher than those in the BMS group ((40.8 +/- 11.4) mm vs. (23.4 +/- 8.7) mm, P<0.001). But the mean diameter of stents in the DES group was smaller than that in the BMS group ((3.1 +/- 0.2) mm vs. (3.3 +/- 0.5) mm, P.<0.001). Average follow-up time was 4.8 +/- 0.7 (1.5-5.0) years in the BMS group and 4.3 +/- 0.5 (1.3-5.0) years in the DES group. Both the 5-year cumulative survival rates and the target vessel revascularization (TVR)-free survival rates of the DES group were significantly higher than those in the BMS group (83.1% vs. 72.9%, Log-rank P=0.044; 77.1% vs. 62.9%, Log-rank P=0.009). The cumulative MACE-free survival rates in the DES group were significantly higher than those in the BMS group (71.2% vs. 51.4%, Log-rank P=0.001). Multivariable Cox regression analysis demonstrated that DES implantation for multiple CTO lesions could significantly reduce the long-term MACE risk after percutaneous coronary intervention (PCI) (HR: 0.436; 95%CI 0.327-0.665, P <0.001). Age over 65 years (HR: 2.018; 95%CI 1.491-3.127, P <0.001) and left ventricular ejection fraction <50% (HR: 1.494; 95%CI 1.125-2.376, P <0.001) were identified as the independent predictors of long-term MACE.Conclusion This study demonstrates the long-term (up to 5 years) efficacy and safety of DES for treatment of multiple coronary CTO lesions, and its superiority compared to BMS in reducing the rates of TVR and MACE. Chin Med J 2010;123(7):789-793

Immediate and Mid-Term Outcomes of Sirolimus-Eluting Stent Implantation for Chronic Total Occlusions

Clinical and Angiographic Outcome after Sirolimus-Eluting Stent Implantation in Aorto-Ostial Lesions.

Safety and Efficacy of the Cypher Select Sirolimus-Eluting Stent in the "real World" - Clinical and Angiographic Results from the China Cypher Select Registry

Three‐year Clinical Outcomes of the Novel Sirolimus‐eluting Bioresorbable Scaffold for the Treatment of De Novo Coronary Artery Disease: A Prospective Patient‐level Pooled Analysis of NeoVas Trials

[Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction]

Sirolimus-Eluting Stents in Real-World Patients with St-Segment Elevation Acute Myocardial Infarction

Short and Intermediate Term Clinical Outcome of Sirolimus-Eluting Stent Implantation in Patients with ST-segment Elevation Myocardial Infarction

Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

Design and Rationale of Targeted Therapy With a Sirolimus-Eluting, Biodegradable Polymer Coronary Stent in Chronic Total Occlusions (TARGET CTO): A Multicenter, Open-Label, Randomized Noninferiority Trial.

Long-term Efficacy and Safety of Drug-Eluting Stent Implantation for Patients with Multiple Coronary Chronic Total Occlusions.

Clinical outcome following aleatory implantation of paclitaxel-eluting or sirolimus-eluting stents in complex coronary lesions.

Mid-term treatment results of drug-eluting stent implantation for patients with multivessel chronic total coronary occlusion lesions

Head-To-Head Comparison Of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents In Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis Of 76 Studies

Five-Year Comparative Efficacy of Everolimus-Eluting vs. Resolute Zotarolimus-Eluting Stents in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

Comparison of Long-Term Safety of Coronary Sirolimus-Eluting Stent with Bare Metal Stent Implantation in Patients with Multivessel Coronary Disease

TCT-567 Long-Term Outcomes with an Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent Versus a Cobalt-Chromium Everolimus-Eluting Stent in Single De Novo Coronary Lesions: Four-Year Results of the TARGET I Randomized Controlled Trial

Impact of ultra-thin struts on restenosis after chronic total occlusion recanalization: Insights from the randomized PRISON IV trial

Self-Apposing Stents in Coronary Chronic Total Occlusions: A Pilot Study

Randomized Clinical Trial Comparing Abluminal Biodegradable Polymer Sirolimus-Eluting Stents With Durable Polymer Sirolimus-Eluting Stents: Nine Months Angiographic And 5-Year Clinical Outcomes

Combined Treatment of Native Femoropopliteal Occlusions in Chronic Limb-Threatening Ischemia Using Atherectomy Debulking and a New Sirolimus Drug-Coated Balloon (SELUTION SLR)

One-Year Outcomes of Biodegradable Polymer-Coated Sirolimus-Eluting Coronary Stent in Acute Coronary Syndrome: A Patient-Level Pooled Analysis from Two Indian Registries